药明康德管理团队致客户的公开信 | Bilingual - 推荐阅读

药明康德管理团队致客户的公开信 | Bilingual

2024-02-06

2月5日，药明康德发出一封公开信，全文内容如下：

An Open Letter to our Customers from WuXi AppTec Leadership

For more than 20 years, WuXi AppTec has enabled thousands of customers across the pharmaceutical and life sciences industries to discover, develop, and manufacture new medicines to benefit patients.

We have always been guided by our core value of “doing the right thing and doing it right.” And we remain committed to this ethos despite recent unfounded and misleading claims about our company.

Like many of you, we are concerned by a misguided U.S. legislative initiative to target our company without a fair and transparent review of the facts. We are equally concerned by the serious impact the unwarranted allegations and harmful actions would have on patients who rely on the life-saving and innovative work our customers perform in the United States and around the world.

We want to be clear and set the record straight: WuXi AppTec does not pose a national security risk to any country.

While the U.S. government has determined that certain companies do pose such a risk to the United States and has imposed sanctions against them, WuXi AppTec has never been subject to any such determination or sanction. We welcome regulatory oversight of our industry, including the proposed evaluation of biotech companies in the recent legislation. But we strongly object to blanket allegations and preemptive actions against our company without due process.

WuXi AppTec has a strong track record of upholding the highest intellectual property, data and privacy protection standards, as well as maintaining the trust of our customers. Our number one priority continues to be providing customers with resources and capabilities to advance discoveries in the life sciences and deliver treatments to those in need.

As deliberations on this legislation continue, we are actively correcting the unfounded and misleading claims about our company. We are confident that upon considering the facts, U.S. lawmakers will understand that WuXi AppTec does not in any way pose a national security risk to any country. Instead, we serve as a valued contributor to the pharmaceutical and life sciences industries.

Sincerely,

Ge Li, Ph.D., Chairman & CEO

Minzhang Chen, Ph.D., Co-CEO

Steve Yang, Ph.D., Co-CEO

药明康德管理团队致客户的公开信

（参考中文稿·以英文稿为准）

二十多年来，药明康德通过对万千医药健康行业客户的赋能，帮助他们不断提高新药研发及生产效率，推动更多新药、好药早日问世以造福全球病患。

公司始终秉持“做对的事，把事做好”的核心价值观，哪怕近期遭受一些并无根据且具误导的无端指控，我们的核心价值观不会有任何动摇。

您可能注意到，最近在美国国会有某项拟议立法草案提及药明康德。对一项立法提议在没有对事实进行公平公开的评估之前就针对个别公司做出预判结论的做法，我们相信有诸多各方和我们一样感到担忧。我们担忧，这些并无确实根据的指称将会影响到我们赋能美国及全球客户的新药研发项目，进而对病患救治产生影响。

因此，我们觉得有必要在此明确声明：药明康德在过去不曾、现在和未来都不会对任何国家的国家安全构成风险。

美国政府曾将某些公司认定为对美国国家安全构成风险，并对其实施制裁。但是，药明康德从未收到该等认定或受到制裁。作为全球医药健康生态圈的一员，我们一直接受并欢迎行业监管，也愿意接受立法草案中提议的对生物技术公司的风险评估。但我们明确反对未经正当程序对公司进行无端指控和预判定性的做法。

一直以来，药明康德始终恪守知识产权、数据和隐私保护的最高标准，并赢得了全球大量客户的信赖。我们会坚持公司一贯的首要任务，把赋能客户做到极致，助力他们加速生命科学领域的创新和突破，为全球患者研发、生产出更多新药、好药。